Mein Warenkorb

LRRC15

LRRC15 Molekülinformation

Englischer NameLeucine-rich repeat-containing protein 15Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel0Target-AliasLRRC15,Leucine-rich repeat-containing protein 15,hLib,Leucine Rich Repeat Containing 15,Leucine-Rich Repeat Protein Induced By Beta-Amyloid Homolog,LIB,Leucine-Rich Repeat Protein Induced By Beta Amyloid
Höchste Forschungs- und EntwicklungsphasePreclinical
Englischer NameLeucine-rich repeat-containing protein 15
Target-AliasLRRC15,Leucine-rich repeat-containing protein 15,hLib,Leucine Rich Repeat Containing 15,Leucine-Rich Repeat Protein Induced By Beta-Amyloid Homolog,LIB,Leucine-Rich Repeat Protein Induced By Beta Amyloid
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePreclinical

LRRC15 Molekülhintergrund

LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.

LRRC15 Molekülalias

Leucine-rich repeat-containing protein 15,LRRC15,LIB,hLib
  • Molekülinformation
  • Produktliste
Kontaktieren Sie uns